# A study of pazopanib in metastatic merkel cell carcinoma

Submission date	Recruitment status	Prospectively registered		
26/03/2013	No longer recruiting	Protocol		
Registration date	Overall study status	Statistical analysis plan		
26/03/2013	Completed  Condition category	☐ Results		
Last Edited		Individual participant data		
11/12/2014	Cancer	<ul><li>Record updated in last year</li></ul>		

# Plain English summary of protocol

http://www.cancerresearchuk.org/cancer-help/trials/a-trial-of-pazopanib-for-merkel-cell-carcinoma-ukmcc-01

# Contact information

# Type(s)

Scientific

#### Contact name

Dr Joshua Savage

#### **ORCID ID**

https://orcid.org/0000-0003-0599-0245

#### Contact details

Cancer Research UK Clinical Trials Unit School of Cancer Studies University of Birmingham Edgbaston Birmingham United Kingdom B15 2TT

UKMCC-01@trials.bham.ac.uk

# Additional identifiers

Clinical Trials Information System (CTIS)

2011-003226-27

Protocol serial number

# Study information

# Scientific Title

A Phase II study of pazopanib in metastatic merkel cell carcinoma

# Acronym

**UKMCC-01** 

# **Study objectives**

Merkel cell carcinoma (MCC) is a rare neuroendocrine cancer of the skin with poor prognosis. The annual incidence is thought to be 0.6 per 100,000 of population, with approximately 400 cases per year in the UK. In this study we aim to determine if pazopanib is clinically active, as determined by response rate using the RECIST scoring, in advanced MCC and thus warrants further investigation in a phase III trial. Furthermore, through a translational sub-study, we aim to explore the biological features of MCC and relate these to clinical outcome in order to identify possible clinical biomarkers and therapeutic targets.

More details can be found at: http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=13736

# Ethics approval required

Old ethics approval format

# Ethics approval(s)

NRES Committee North West - Haydock, 02/11/2012, ref: 12/WM/0182

# Study design

Non-randomised; Interventional; Design type: Treatment

# Primary study design

Interventional

# Study type(s)

Treatment

# Health condition(s) or problem(s) studied

Topic: National Cancer Research Network; Subtopic: Melanoma; Disease: Melanoma

#### **Interventions**

Treatment with Pazopanib,  $4 \times 200$  mg tablets once daily by mouth for 28 days. Treatment will continue until disease progression.

Follow Up Length: 60 month(s)

Study Entry Details: Registration, followed by trial entry on completion of successful screening

## Intervention Type

Drug

## **Phase**

Phase II

# Drug/device/biological/vaccine name(s)

Pazopanib

# Primary outcome(s)

Clinical response rate; Timepoint(s): Proportion of patients with complete response or confirmed partial response throughout trial

# Key secondary outcome(s))

- 1. Disease control rate; Timepoint(s): % of patients that have stable disease, a PR, or a CR for more than 12 weeks
- 2. Duration of response; Timepoint(s): Time from date of first response (partial/complete) to date of progression or death from any cause
- 3. Overall survival; Timepoint(s): Time from entry into the trial until death from any cause
- 4. PFS; Timepoint(s): Time from entry into the trial until disease progression or death from any cause

# Completion date

01/08/2019

# **Eligibility**

# Key inclusion criteria

Current inclusion criteria as of 17/01/2014:

- 1. Patients with histologically proven, unresectable, MCC that is metastatic and/or for which durable control cannot be achieved with surgery or radiotherapy
- 2. RECIST measurable disease, as per RECIST version 1.1
- 3. Age ≥18 years, either sex
- 4. Performance status 0, 1 or 2 assessed using the Eastern Cooperative Oncology Group scale
- 5. Received previous first line chemotherapy or considered unsuitable for chemotherapy
- 6. Toxicities from first line chemotherapy resolved to at least grade 1
- 7. Adequate end organ function
- 7.1. Renal function tests: serum creatinine  $\leq 150 \, \mu mol/L$ . If serum creatinine is >150  $\mu mol/L$ , calculated creatinine clearance must be  $\geq 30 \, ml/min$  Urine Protein to Creatinine ratio (UPC) <1. If UPC  $\geq 1$ , then a 24-hour protein must be assessed. Patients must have 24-hour protein value <1 g to be eligible. Alternatively, Albumin/Creatinine ratio may be measured (in accordance with institutional policy, same test to be used for study duration)
- 7.2. Liver function tests: Total serum bilirubin  $\leq$ 1.5 X Upper Limit Normal (ULN), Alanine Aminotransferase or Aspartate Aminotransferase (in accordance with institutional policy, same test to be used for study duration)  $\leq$ 2.5 X ULN (or  $\leq$ 5 X ULN if liver metastases are present)
- 7.3. Haematology: Absolute Neutrophil Count (ANC)  $\geq$ 1.5 X 109/L, Serum creatinine  $\leq$ 150 µmol/L. If serum creatinine >150 µmol/L, calculated creatinine clearance must be  $\geq$ 30 ml/min, Urine Protein to Creatinine ratio (UPC) <1. If UPC  $\geq$ 1, then a 24-hour protein must be assessed. Patients must have 24hour protein value <1 g to be eligible
- 7.4. Liver function tests: Total serum bilirubin  $\leq$ 1.5 X Upper Limit Normal (ULN), Alanine Aminotransferase or Aspartate Aminotransferase (in accordance with institutional policy, same test to be used for study duration)  $\leq$ 2.5 X ULN (or  $\leq$ 5 X ULN if liver metastases are present) 7.5. Haematology: Absolute Neutrophil Count (ANC)  $\geq$ 1.5 X 109/L Haemoglobin  $\geq$ 10 g/dL

Platelets ≥100 X 10 to the power of 9/L

- 7.6. Coagulation test: International Normalized Ratio ≤1.2 X ULN, unless on therapeutic anticoagulation. For patients on therapeutic anticoagulation, INR should be stable and in target range
- 8. Able to give written informed consent
- 9. Women of childbearing potential, or men in a relationship with a woman of childbearing age, prepared to adopt adequate contraceptive measures if sexually active
- 10. Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures

#### Previous inclusion criteria:

- 1. Patients with histologically proven, unresectable, MCC that is metastatic and/or for which durable control cannot be achieved with surgery or radiotherapy
- 2. RECIST measurable disease, as per RECIST version 1.1
- 3. Age ≥18 years, either sex
- 4. Performance status 0, 1 or 2 assessed using the Eastern Cooperative Oncology Group scale
- 5. Received previous first line chemotherapy or considered unsuitable for chemotherapy
- 6. Toxicities from first line chemotherapy resolved to at least grade 1
- 7. Adequate end organ function
- 7.1. Renal function tests: Serum creatinine  $\leq$ 150 µmol/L. If serum creatinine >150 µmol/L, calculated creatinine clearance must be  $\geq$ 30 ml/min Urine Protein to Creatinine ratio (UPC) <1. If UPC  $\geq$ 1, then a 24-hour protein must be assessed. Patients must have 24-hour protein value <1 g to be eligible
- 7.2. Liver function tests: Total serum bilirubin  $\leq$ 1.5 X Upper Limit Normal (ULN), Alanine Aminotransferase or Aspartate Aminotransferase (in accordance with institutional policy, same test to be used for study duration)  $\leq$ 2.5 X ULN (or  $\leq$ 5 X ULN if liver metastases are present)
- 7.3. Haematology: Absolute Neutrophil Count (ANC)  $\geq$ 1.5 X 109/L, Serum creatinine  $\leq$ 150 µmol/L. If serum creatinine >150 µmol/L, calculated creatinine clearance must be  $\geq$ 30 ml/min, Urine Protein to Creatinine ratio (UPC) <1. If UPC  $\geq$ 1, then a 24-hour protein must be assessed. Patients must have 24hour protein value <1 g to be eligible
- 7.4. Liver function tests: Total serum bilirubin  $\leq$ 1.5 X Upper Limit Normal (ULN), Alanine Aminotransferase or Aspartate Aminotransferase (in accordance with institutional policy, same test to be used for study duration)  $\leq$ 2.5 X ULN (or  $\leq$ 5 X ULN if liver metastases are present)
- 7.5. Haematology: Absolute Neutrophil Count (ANC)  $\geq$ 1.5 X 109/L Haemoglobin  $\geq$ 10 g/dL Platelets  $\geq$ 100 X 10 to the power of 9/L
- 7.6. Coagulation test: International Normalized Ratio ≤1.2 X ULN
- 8. Able to give written informed consent
- 9. Women of childbearing potential, or men in a relationship with a woman of childbearing age, prepared to adopt adequate contraceptive measures if sexually active
- 10. Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures

# Participant type(s)

Patient

# Healthy volunteers allowed

No

# Age group

Adult

# Lower age limit

## Sex

All

# Key exclusion criteria

- 1. Previous malignancies. (Unless agreed in writing by the Chief Investigator or a clinical Coinvestigator, investigators are advised to call the Trial Office).
- 2. Known brain metastases unless radically treated with surgery or radiotherapy >6 months prior to study entry and without evidence of central nervous system progression since treatment
- 3. History in the past 6 months of cerebral or clinically significant gastrointestinal haemorrhage
- 4. Haemoptysis within 6 weeks prior to first dose of study medication
- 5. Evidence of active bleeding or bleeding diathesis
- 6. Uncontrolled hypertension defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg. Initiation or adjustment of antihypertensive medication(s) is permitted prior to trial entry
- 7. Presence of uncontrolled infection
- 8. History of malabsorption, major gastrointestinal tract resection or other pathology likely to affect absorption of study medication
- 9. Prolongation of the QT interval (QTc) >480 milliseconds
- 10. History of any one or more of the following cardiovascular conditions within the past 6 months: Cardiac angioplasty or stenting Myocardial infarction Unstable angina Coronary artery bypass graft surgery Symptomatic peripheral vascular disease Class III or IV congestive heart failure, as defined by the New York Heart Association Functional Classification
- 11. History of cerebrovascular accident including transient ischemic attack within the past 12 months
- 12. History of pulmonary embolism or untreated deep venous thrombosis within the past 6 months. Patients with a history of thromboembolic disease who are on treatment with therapeutic anticoagulating agents are eligible
- 13. Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels
- 14. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drug chemically related to pazopanib
- 15. Major surgery or trauma <4 weeks prior to starting study medication and/or presence of any nonhealing wound, fracture, or ulcer
- 16. Radiotherapy <2 weeks prior to starting study medication
- 17. Known HIV, Hepatitis B or C infection
- 18. Pregnant (female patients of child bearing potential should have a urine or blood Human Chorionic Gonadotropin test performed to rule out pregnancy prior to trial entry)
- 19. Lactating females. Patients who agree to discontinue nursing 14 days prior to commencing treatment and do not nurse throughout all the treatment period are eligible
- 20. The use of the following medication is prohibited: Previous therapy with agents that target the Vascular Endothelial Growth Factor (VEGF) or Platelet derived Growth Factor (PDGF) pathways Chemotherapy, immunotherapy, biologic therapy, investigational therapy, hormone therapy or use of any prohibited medications within 14 days prior to the first dose of study medication Use of drugs which are known strong CYP3A4 inhibitors or inducers within 14 days prior to the first dose of study medication
- 21. Any serious and/or unstable preexisting medical, psychiatric, or other conditions that could interfere with patients safety, obtaining informed consent or compliance to the study 22. Other contraindications to study medication

#### Date of first enrolment

# Date of final enrolment 21/12/2015

# Locations

# Countries of recruitment

**United Kingdom** 

England

# Study participating centre Cancer Research UK Clinical Trials Unit

School of Cancer Studies University of Birmingham Edgbaston Birmingham United Kingdom B15 2TT

# Sponsor information

# Organisation

University of Birmingham (UK)

#### **ROR**

https://ror.org/03angcq70

# Funder(s)

# Funder type

Industry

## **Funder Name**

Cancer Research UK (UK); Grant Codes: C17955/A12806; CTAAC

## Alternative Name(s)

CR\_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

# **Funding Body Type**

Private sector organisation

# **Funding Body Subtype**

Other non-profit organizations

#### Location

**United Kingdom** 

# **Funder Name**

GlaxoSmithKline

# Alternative Name(s)

GlaxoSmithKline plc., GSK plc., GlaxoSmithKline plc, GSK

# **Funding Body Type**

Government organisation

# Funding Body Subtype

For-profit companies (industry)

## Location

**United Kingdom** 

# **Results and Publications**

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not expected to be made available

# **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes